8-K: REGENXBIO Secures Up to $250 Million in Royalty Monetization Agreement, Extending Cash Runway into Early 2027

REGENXBIO has entered into a royalty bond agreement with Healthcare Royalty for up to $250 million, securing $150 million upfront and extending its cash runway into early 2027.

Summary

• REGENXBIO Inc. has entered into a loan agreement with an affiliate of HealthCare Royalty Management, LLC (HCRx) for up to $250 million.
• The loan, termed a Royalty Bond, will be disbursed in three tranches: $150 million was funded on May 16, 2025, $50 million is available if sales of a specified product exceed a threshold by December 31, 2026, and $50 million is available if both parties exercise an option in 2027.
• The Royalty Bond is collateralized by anticipated royalties from net sales under existing license agreements, including those with Novartis for Zolgensma, Nippon Shinyaku for clemidsogene lanparvovec (RGX-121) and RGX-111, and Rocket Pharmaceuticals and Ultragenyx Pharmaceuticals, Inc.
• The interest rate on the Royalty Bond is 9.75% plus the 3-month secured overnight financing rate (SOFR) with a 4.25% SOFR floor.
• REGENXBIO issued a warrant to HCRx to purchase 268,096 shares of the company's common stock at an exercise price of $14.92 per share.
• The proceeds from the Royalty Bond will be used to purchase assets related to the Royalty Interest.
• The agreement extends REGENXBIO's cash runway into early 2027 and allows the company to retain future non-dilutive funding opportunities.
• The Royalty Bond matures 10 years after the closing date, or 12 years if a specified patent term extension occurs.

Sentiment

Score: 8

Explanation: The announcement is positive as it secures significant funding, extends the cash runway, and avoids equity dilution. The terms of the agreement appear reasonable, and management expresses confidence in the company's future prospects.

Positives

• The $150 million secured at closing extends REGENXBIO's cash runway into early 2027.
• The agreement provides access to up to $250 million in non-dilutive funding.
• REGENXBIO retains additional potential non-dilutive funding opportunities, including monetization of a Priority Review Voucher and milestones from AbbVie.
• The financing allows REGENXBIO to advance its late-stage activities and commercial preparations.
• The deal capitalizes on REGENXBIO's position as a late-stage gene therapy company with multiple royalty-generating assets.

Negatives

• The Royalty Bond is collateralized by royalties from key products, potentially limiting future revenue streams.
• The interest rate of 9.75% plus SOFR with a 4.25% floor could be a significant expense.
• REGENXBIO issued warrants to HCRx, which could dilute existing shareholders if exercised.
• The Royalty Bond cannot be voluntarily prepaid.

Risks

• Failure to achieve specified sales thresholds could prevent access to the additional $50 million tranche by December 31, 2026.
• The Royalty Interest may be insufficient to cover interest payments, leading to accrued interest being added to the principal balance.
• Defaulting on the Loan Agreement could allow HCRx to declare the loan immediately due and payable.
• The value of the warrants issued to HCRx could be affected by fluctuations in REGENXBIO's stock price.

Future Outlook

REGENXBIO expects the financing to extend its cash runway into early 2027 and enable the company to advance its late-stage activities, including potential FDA approval of RGX-121, top-line data readout and BLA submission for RGX-202, and top-line data readouts for two pivotal studies of subretinal ABBV-RGX-314.

Management Comments

• Mitchell Chan, CFO of REGENXBIO, stated that the financing extends the company's runway beyond multiple meaningful milestones and enables them to retain future potential non-dilutive opportunities.
• Clarke Futch, Chairman and CEO of HCRx, noted that the deal demonstrates HCRx's commitment to providing innovative capital structures to benefit their clients and their shareholders.

Industry Context

This agreement reflects a trend in the biotechnology industry of monetizing royalty streams to secure non-dilutive funding. Royalty financing allows companies to leverage existing assets to fund ongoing research and development without issuing new equity.

Comparison to Industry Standards

• Royalty financing is a common strategy in the biotech industry, with companies like Ligand Pharmaceuticals and Royalty Pharma specializing in acquiring royalty streams.
• The interest rate of 9.75% plus SOFR with a 4.25% floor is within the typical range for royalty-backed loans, reflecting the risk associated with the underlying assets.
• The warrant coverage of 268,096 shares is also a standard feature in royalty financing deals, providing the lender with potential upside from the company's stock performance.
• Compared to straight debt financing, royalty financing is often more attractive for biotech companies as it is non-dilutive and the repayment is tied to the success of the underlying products.

Stakeholder Impact

• Shareholders benefit from the extended cash runway and reduced risk of equity dilution.
• Employees benefit from the increased financial stability of the company.
• Patients may benefit from the accelerated development of new gene therapies.
• HCRx benefits from the potential return on investment from the Royalty Bond and warrants.

Next Steps

• REGENXBIO will file the Loan Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.
• The company will continue to advance its late-stage pipeline, including RGX-121, RGX-202, and ABBV-RGX-314.
• REGENXBIO will explore potential monetization of the Priority Review Voucher for RGX-121.
• HCRx will monitor the performance of the underlying royalty streams and may exercise its warrant to purchase REGENXBIO shares.

Key Dates

Keywords

REGENXBIO, Royalty Bond, Healthcare Royalty, HCRx, Zolgensma, RGX-121, RGX-111, Gene Therapy, Financing, Non-Dilutive, Milestones, Warrants